These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 35190696)

  • 21. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fatty Liver Disease and Hepatocellular Carcinoma: The Pathologist's View.
    Tiniakos DG; Maurício J; Reeves HL
    Adv Exp Med Biol; 2018; 1032():55-69. PubMed ID: 30362090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging novel targets for nonalcoholic fatty liver disease treatment: Evidence from recent basic studies.
    Wang GY; Zhang XY; Wang CJ; Guan YF
    World J Gastroenterol; 2023 Jan; 29(1):75-95. PubMed ID: 36683713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma.
    Takakura K; Oikawa T; Tomita Y; Mizuno Y; Nakano M; Saeki C; Torisu Y; Saruta M
    World J Gastroenterol; 2018 May; 24(18):1989-1994. PubMed ID: 29760542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The common marmoset as a model for the study of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Kramer JA; Grindley J; Crowell AM; Makaron L; Kohli R; Kirby M; Mansfield KG; Wachtman LM
    Vet Pathol; 2015 Mar; 52(2):404-13. PubMed ID: 24913270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research.
    Gottlieb A; Mosthael W; Sowa JP; Canbay A
    Digestion; 2019; 100(2):79-85. PubMed ID: 30537758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms and disease consequences of nonalcoholic fatty liver disease.
    Loomba R; Friedman SL; Shulman GI
    Cell; 2021 May; 184(10):2537-2564. PubMed ID: 33989548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Promising therapies for treatment of nonalcoholic steatohepatitis.
    Noureddin M; Zhang A; Loomba R
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.
    Barritt AS; Gitlin N; Klein S; Lok AS; Loomba R; Malahias L; Powell M; Vos MB; Weiss LM; Cusi K; Neuschwander-Tetri BA; Sanyal A
    Contemp Clin Trials; 2017 Oct; 61():33-38. PubMed ID: 28735109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The therapeutic landscape of non-alcoholic steatohepatitis.
    Perazzo H; Dufour JF
    Liver Int; 2017 May; 37(5):634-647. PubMed ID: 27727520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histopathological Diagnosis of Nonalcoholic Steatohepatitis (NASH).
    Giashuddin S; Alawad M
    Methods Mol Biol; 2022; 2455():1-18. PubMed ID: 35212981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Younossi ZM; Loomba R; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Chalasani NP; Anstee QM; Kowdley KV; George J; Goodman ZD; Lindor K
    Hepatology; 2018 Jul; 68(1):361-371. PubMed ID: 29222911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Will Studies in Nonalcoholic Steatohepatitis Help Manage Alcoholic Steatohepatitis?
    Sundaram V; Morgan TR
    Clin Liver Dis; 2019 Feb; 23(1):157-165. PubMed ID: 30454829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histopathological findings of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Kage M; Aishima S; Kusano H; Yano H
    J Med Ultrason (2001); 2020 Oct; 47(4):549-554. PubMed ID: 33136250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis.
    Branković M; Jovanović I; Dukić M; Radonjić T; Oprić S; Klašnja S; Zdravković M
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triggering and resolution of inflammation in NASH.
    Schuster S; Cabrera D; Arrese M; Feldstein AE
    Nat Rev Gastroenterol Hepatol; 2018 Jun; 15(6):349-364. PubMed ID: 29740166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies.
    Wattacheril J; Issa D; Sanyal A
    Annu Rev Pharmacol Toxicol; 2018 Jan; 58():649-662. PubMed ID: 29058997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease.
    Puengel T; Liu H; Guillot A; Heymann F; Tacke F; Peiseler M
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis.
    Satiya J; Snyder HS; Singh SP; Satapathy SK
    Transl Gastroenterol Hepatol; 2021; 6():60. PubMed ID: 34805582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.